Immunome Company Leadership

Immunome Management Team Effectiveness

The company has return on total asset (ROA) of (0.4648) % which means that it has lost $0.4648 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9304) %, meaning that it created substantial loss on money invested by shareholders. Immunome's management efficiency ratios could be used to measure how well Immunome manages its routine affairs as well as how well it operates its assets and liabilities. As of the 7th of January 2026, Return On Tangible Assets is likely to drop to -1.15. In addition to that, Return On Capital Employed is likely to drop to -1.55. At this time, Immunome's Total Assets are very stable compared to the past year. As of the 7th of January 2026, Non Current Assets Total is likely to grow to about 22.8 M, while Other Assets are likely to drop 0.86. As of the 7th of January 2026, Common Stock Shares Outstanding is likely to grow to about 70.8 M, though Net Loss is likely to grow to (32.1 M). Immunome has a total of 110.34 Million outstanding shares. The majority of Immunome outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Immunome to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Immunome. Please pay attention to any change in the institutional holdings of Immunome as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Immunome in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Immunome, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Immunome Workforce Comparison

Immunome Insider Trading History

Immunome Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Immunome often depends on how effective the management is. Immunome management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immunome management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immunome management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.